Ajan Reginald, CEO of Celixir (formerly Cell Therapy Limited) is an entrepreneur based in London, UK. Ajan Reginald is a graduate in dental surgery and masters in Biotechnology with a combinational background in science and business. A vivid hockey player, Ajan has played at international levels and is actively involved in the work of Hockey.
Ajan Reginald is currently the co-founder and the Chief Executive Officer of Celixir, which was founded by him in 2009 with Nobel Laureate Professor Sir Martin Evans. The original name of the company at the time of foundation was Cell therapy Limited.
Celixir is a private British regenerative medicine company that discovers and develops life-saving and life-altering regenerative medicines for patient’s cell and gene therapies for patients with the greatest medical need. Celixir’s unique rational design approach drives in-house discovery and has created a broad pipeline of cell and gene therapy medicines, with seven of these currently being taken forward through the development cycle.
At Celixir the pipeline is led by their investigational cardiac tissue engineered, cell therapy product, HeartcelTM which was designed keeping in mind to treat patients with heart failure undergoing coronary artery bypass graft (CABG) These HeartcelTM are injected during the bypass surgery surrounding the cardiac scar tissue in one single application. Another one of Celixir’s products is in late-stage clinical development called TendoncelTM, It is for tendon repair and is currently being tested in patients who suffer from tennis elbow. In its clinical stage pipeline, Celixir is also progressing three oncology products and two further cardiac products through the pre-IND stage..
Ajan Reginald before starting on with the entrepreneurial mode has served as the Global Head of Emerging Technologies and Business Development Director at Roche Pharma where he has overseen the identification, acquisition and development of the next generation of quantum leap of biopharma technologies and products. He joined Roche as a Business Development Director where he completed over 30 M&A and licensing transactions including a $1.3B licensing transaction with Alnylam.
Before joining Roche, Ajan Reginald worked with the Boston Consulting Group (BCG) in the USA & Zurich as a member of both the Life Sciences Practice Area and Intellectual Property Group. Ajan Reginald was formerly a dental surgeon but he had to retire after getting injured during a hockey match which resulted in a visual impairment.
Ajan Reginald is a Fulbright Scholar, graduate of the London Hospital School of Medicine and Dentistry (University of London) and holds an MBA from the Kellogg Business School at Northwestern University and an MSc in Experimental Therapeutics from Oxford University. He has also completed the Harvard Business School Advanced Management Program.
ความคิดเห็น